[go: up one dir, main page]

BR9811262A - Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a. - Google Patents

Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a.

Info

Publication number
BR9811262A
BR9811262A BR9811262-7A BR9811262A BR9811262A BR 9811262 A BR9811262 A BR 9811262A BR 9811262 A BR9811262 A BR 9811262A BR 9811262 A BR9811262 A BR 9811262A
Authority
BR
Brazil
Prior art keywords
lipid
surfactant
aqueous
derivative
auxiliary
Prior art date
Application number
BR9811262-7A
Other languages
English (en)
Inventor
R Thomas Crane
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of BR9811262A publication Critical patent/BR9811262A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES AUXILIARES IMUNOLóGICAS AQUOSAS DE LIPìDIO DE MONOFOSFORILA A"<D>. Uma composição auxiliar aquosa que compreende um derivado de lipídio A atenuado e um tensoativo ou tensoativos melhora a resposta imunológica em um animal de sangue quente a um antígeno de proteína. Os derivados de lipídio A atenuado úteis de acordo com a invenção em questão incluem lipídio de monofosforila A e lipídio de monofosforila A 3-O-desacilada. Um tensoativo ou misturas de tensoativos são dissolvidos em um solvente. 1,2-Dipalmitoil-sn-glícero-3-fosfocolina é um solvente preferido. O tensoativo dissolvido é adicionado a um derivado de lipídio A atenuado para obter uma mistura. A razão molar de derivado de lipídio A atenuado para tensoativo na mistura é aproximadamente 4:1. O solvente é evaporado e é adicionada água à película resultante. A suspensão é submetida à aplicação de ondas sonoras em um banho de água a 60 °C até que ela se torne clara. Os animais administrados com a formulação auxiliar apresentaram respostas de anticorpo aumentadas a um dado antígeno assim como apresentaram respostas proliferativas de linfócito e linfócito T citotóxico melhoradas. A administração intranasal da composição auxiliar aquosa e um antígeno estimula a produção de IgA secretado de soro e mucosal.
BR9811262-7A 1997-04-01 1998-04-01 Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a. BR9811262A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83107397A 1997-04-01 1997-04-01
PCT/US1998/006528 WO1998043670A2 (en) 1997-04-01 1998-04-01 Aqueous immunologic adjuvant compositions of monophosphoryl lipid a

Publications (1)

Publication Number Publication Date
BR9811262A true BR9811262A (pt) 2000-10-17

Family

ID=25258229

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811262-7A BR9811262A (pt) 1997-04-01 1998-04-01 Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a.

Country Status (18)

Country Link
EP (1) EP0971739B1 (pt)
JP (1) JP5019494B2 (pt)
KR (1) KR100603884B1 (pt)
CN (2) CN1259052A (pt)
AT (1) ATE278419T1 (pt)
AU (1) AU743114B2 (pt)
BR (1) BR9811262A (pt)
CA (1) CA2284586C (pt)
DE (1) DE69826842T2 (pt)
ES (1) ES2227825T3 (pt)
HU (1) HUP0001403A3 (pt)
IL (2) IL132126A0 (pt)
NO (1) NO994760L (pt)
NZ (1) NZ338101A (pt)
PL (1) PL190237B1 (pt)
PT (1) PT971739E (pt)
TR (1) TR199902437T2 (pt)
WO (1) WO1998043670A2 (pt)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
DE60131670T2 (de) 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
PT1361890E (pt) 2001-02-23 2011-06-07 Glaxosmithkline Biolog Sa Formulações vacinais de influenza para distribuição intradérmica
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
US20100221284A1 (en) 2001-05-30 2010-09-02 Saech-Sisches Serumwerk Dresden Novel vaccine composition
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
CN101203605B (zh) * 2004-12-17 2016-01-27 由卫生福利和体育大臣代表的荷兰王国 革兰氏阴性菌的lps的脱酰基化
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0504436D0 (en) 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
ES2524572T3 (es) 2005-04-29 2014-12-10 Glaxosmithkline Biologicals S.A. Procedimiento novedoso de prevención o tratamiento de infección por M. tuberculosis
EA014314B1 (ru) * 2005-08-02 2010-10-29 Новартис Вэксинес Энд Дайэгностикс Срл Пониженная интерференция между маслосодержащими адъювантами и антигенами, содержащими поверхностно-активные вещества
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8018440B2 (en) 2005-12-30 2011-09-13 Microsoft Corporation Unintentional touch rejection
EP2486938B1 (en) 2006-09-26 2018-05-09 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8836648B2 (en) 2009-05-27 2014-09-16 Microsoft Corporation Touch pull-in gesture
MX360448B (es) 2009-06-05 2018-11-01 Infectious Disease Res Inst Adyuvantes sinteticos de glucopiranosil-lipido.
FR2954703B1 (fr) 2009-12-28 2013-12-13 Chu Nantes Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
US9411504B2 (en) 2010-01-28 2016-08-09 Microsoft Technology Licensing, Llc Copy and staple gestures
US8261213B2 (en) 2010-01-28 2012-09-04 Microsoft Corporation Brush, carbon-copy, and fill gestures
US9519356B2 (en) 2010-02-04 2016-12-13 Microsoft Technology Licensing, Llc Link gestures
US9310994B2 (en) 2010-02-19 2016-04-12 Microsoft Technology Licensing, Llc Use of bezel as an input mechanism
US8799827B2 (en) 2010-02-19 2014-08-05 Microsoft Corporation Page manipulations using on and off-screen gestures
US9367205B2 (en) 2010-02-19 2016-06-14 Microsoft Technolgoy Licensing, Llc Radial menus with bezel gestures
US9075522B2 (en) 2010-02-25 2015-07-07 Microsoft Technology Licensing, Llc Multi-screen bookmark hold gesture
US8707174B2 (en) 2010-02-25 2014-04-22 Microsoft Corporation Multi-screen hold and page-flip gesture
US8751970B2 (en) 2010-02-25 2014-06-10 Microsoft Corporation Multi-screen synchronous slide gesture
US9454304B2 (en) 2010-02-25 2016-09-27 Microsoft Technology Licensing, Llc Multi-screen dual tap gesture
US8612874B2 (en) 2010-12-23 2013-12-17 Microsoft Corporation Presenting an application change through a tile
US8689123B2 (en) 2010-12-23 2014-04-01 Microsoft Corporation Application reporting in an application-selectable user interface
US9423951B2 (en) 2010-12-31 2016-08-23 Microsoft Technology Licensing, Llc Content-based snap point
US9383917B2 (en) 2011-03-28 2016-07-05 Microsoft Technology Licensing, Llc Predictive tiling
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
EA027236B1 (ru) 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
US9658766B2 (en) 2011-05-27 2017-05-23 Microsoft Technology Licensing, Llc Edge gesture
US9104307B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9104440B2 (en) 2011-05-27 2015-08-11 Microsoft Technology Licensing, Llc Multi-application environment
US9158445B2 (en) 2011-05-27 2015-10-13 Microsoft Technology Licensing, Llc Managing an immersive interface in a multi-application immersive environment
US9557909B2 (en) 2011-09-09 2017-01-31 Microsoft Technology Licensing, Llc Semantic zoom linguistic helpers
US9244802B2 (en) 2011-09-10 2016-01-26 Microsoft Technology Licensing, Llc Resource user interface
US9146670B2 (en) 2011-09-10 2015-09-29 Microsoft Technology Licensing, Llc Progressively indicating new content in an application-selectable user interface
AU2012308149A1 (en) 2011-09-12 2014-03-27 Sheena Mary Geraldine MCCORMACK Methods and compositions for raising an immune response to HIV
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
US10232035B2 (en) 2012-09-14 2019-03-19 The Regents Of The University Of Colorado, A Body Corporate Conditionally replication deficient herpes virus and use thereof in vaccines
US9582122B2 (en) 2012-11-12 2017-02-28 Microsoft Technology Licensing, Llc Touch-sensitive bezel techniques
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US9477337B2 (en) 2014-03-14 2016-10-25 Microsoft Technology Licensing, Llc Conductive trace routing for display and bezel sensors
KR102297357B1 (ko) * 2014-03-26 2021-09-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 돌연변이 스태필로코쿠스 항원
JP6820830B2 (ja) 2014-07-18 2021-01-27 ユニヴァーシティ オブ ワシントン がんワクチン組成物およびその使用方法
EP3138579A1 (en) 2015-09-05 2017-03-08 Biomay Ag Fusion protein for use in the treatment of a hepatitis b virus infection
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
EP3678695A1 (en) 2017-09-08 2020-07-15 Infectious Disease Research Institute Liposomal formulations comprising saponin and methods of use
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
EP3569612A1 (en) 2018-05-18 2019-11-20 Biomay Ag Treatment and prevention of house dust mite allergies
IL286467B1 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc Methods for producing bioconjugates of E. COLI O-antigen polysaccharides, preparations thereof and methods for using them
IL286394B2 (en) 2019-03-18 2025-10-01 Janssen Pharmaceuticals Inc E. COLI O-antigen polysaccharide bioconjugates, methods for their production and methods for their use
KR20220107166A (ko) 2019-10-02 2022-08-02 얀센 백신스 앤드 프리벤션 비.브이. 스타필로코커스 펩티드 및 사용 방법
EP4090363B1 (en) 2020-01-16 2024-09-04 Janssen Pharmaceuticals, Inc. Fimh mutant, compositions therewith and use thereof
JP7481585B2 (ja) 2020-09-17 2024-05-10 ヤンセン ファーマシューティカルズ，インコーポレーテッド 多価ワクチン組成物及びその使用
TW202241929A (zh) 2021-01-12 2022-11-01 美商詹森藥物公司 ＦｉｍＨ突變體、其組成物及其用途
WO2022208430A1 (en) 2021-04-01 2022-10-06 Janssen Pharmaceuticals, Inc. Production of e. coli o18 bioconjugates
WO2022251444A1 (en) * 2021-05-27 2022-12-01 Revelation Biosciences, Inc. Mpla compositions and methods of use
CN121221758A (zh) * 2025-12-02 2025-12-30 华诺泰生物医药科技(成都)有限公司 一种即用型稳定3d-mla佐剂溶液的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5068191A (en) * 1989-08-31 1991-11-26 The Biomembrane Institute Purified histo-blood group a glycosyltransferase and antibodies thereto
US5552141A (en) * 1991-10-30 1996-09-03 Ribi; Hans O. Polymeric immunological adjuvants
CZ289476B6 (cs) * 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby

Also Published As

Publication number Publication date
PL190237B1 (pl) 2005-11-30
JP5019494B2 (ja) 2012-09-05
DE69826842D1 (de) 2004-11-11
TR199902437T2 (xx) 2000-01-21
NO994760D0 (no) 1999-09-30
IL132126A0 (en) 2001-03-19
IL132126A (en) 2006-10-05
HUP0001403A2 (hu) 2000-09-28
NZ338101A (en) 2002-03-28
KR20010005882A (ko) 2001-01-15
CN1326564C (zh) 2007-07-18
EP0971739B1 (en) 2004-10-06
EP0971739A2 (en) 2000-01-19
KR100603884B1 (ko) 2006-07-24
ATE278419T1 (de) 2004-10-15
NO994760L (no) 1999-11-26
ES2227825T3 (es) 2005-04-01
HK1026613A1 (en) 2000-12-22
CA2284586A1 (en) 1998-10-08
WO1998043670A2 (en) 1998-10-08
HUP0001403A3 (en) 2003-05-28
CN1575815A (zh) 2005-02-09
CA2284586C (en) 2011-02-08
PT971739E (pt) 2004-12-31
AU743114B2 (en) 2002-01-17
WO1998043670A3 (en) 1998-12-30
AU6947398A (en) 1998-10-22
DE69826842T2 (de) 2005-11-24
JP2001526640A (ja) 2001-12-18
CN1259052A (zh) 2000-07-05
PL336698A1 (en) 2000-07-03

Similar Documents

Publication Publication Date Title
BR9811262A (pt) Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a.
DE60037514D1 (de) Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
ES2572834T3 (es) Complejos inmunogénicos y métodos relacionados con los mismos
ATE249844T1 (de) Immunologische kombinationsmittel und dazugehörige verfahren
DE3381396D1 (de) Formulierung nicht irritierender ophthalmischer waesseriger zusammensetzungen fuer okular-therapeutische mittel.
MD1586F2 (ro) Inducere a unui raspuns citotoxic T-limfocitar
BR0010323A (pt) Composições imunogênicas, kit e método de confecção da mesma para uso na imunização de um mamìfero
KR970000249A (ko) 바이러스 백신용 보조제
BR0010682A (pt) Novas composições
ATE131471T1 (de) An fette gebundene aminosäuren, peptide oder deren derivate
DK0789590T3 (da) Chitosaninduceret immunforstærkning
AU751051B2 (en) Adjuvant comprising pulmonary surfactant
NO179094C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for påföring på slimhinnen
ES2148475T3 (es) Procedimiento para elaborar formulaciones solidas que contienen agentes tensioactivos de oxidos de aminas.
FI845019L (fi) Farmaceutiskt preparat foer behandling av reumatiska sjukdomar.
DE59200928D1 (de) Alkylethercarbonsäuretauride.
SE8402199L (sv) Farmaceutiskt preparat innehallande co-dergocrin och en kalciumantagonist
JPH08183742A (ja) 経鼻ワクチンリポソーム
LV12627A (lv) Aqueous prolonged release formulation
KR0178422B1 (ko) 한탄 바이러스의 펩타이드 항원을 함유하는 리포좀
SE8605513D0 (sv) Ny peptid och immunologiskt aktiva foreningar

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: CORIXA CORPORATION (US)

Free format text: TRANSFERIDO POR FUSAO DE: RIBI IMMUNOCHEM RESEARCH, INC.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements